Cited by 245Bone Metabolism and DiseasesBone health and osteoporosis researchBone and Dental Protein Studies

RANKL Expression Is Related to the Differentiation State of Human Osteoblasts

Atkins, Gerald J, Kostakis, Panagiota, Pan, Beiqing, Farrugia, Amanda, Gronthos, Stan, Evdokiou, Andreas, Harrison, Kate, Findlay, David M +1 more·2003·Journal of Bone and Mineral Research

Abstract

Human osteoblast phenotypes that support osteoclast differentiation and bone formation are not well characterized. Osteoblast differentiation markers were examined in relation to RANKL expression. RANKL expression was induced preferentially in immature cells. These results support an important link between diverse osteoblast functions. Cells of the osteoblast lineage support two apparently distinct functions: bone formation and promotion of osteoclast formation. The aim of this study was to examine the relationship between these phenotypes in human osteoblasts (NHBC), in terms of the pre-osteoblast marker, STRO-1, and the mature osteoblast marker, alkaline phosphatase (AP), and the expression of genes involved in osteoclast formation, RANKL and OPG. The osteotropic stimuli, 1α,25(OH)2vitamin D3 (vitD3) and dexamethasone, were found to have profound proliferative and phenotypic effects on NHBCs. VitD3 inhibited NHBC proliferation and increased the percentage of cells expressing STRO-1 over an extended culture period, implying that vitD3 promotes and maintains an immature osteogenic phenotype. Concomitantly, RANKL mRNA expression was upregulated and maintained in NHBC in response to vitD3. Dexamethasone progressively promoted the proliferation of AP-expressing cells, resulting in the overall maturation of the cultures. Dexamethasone had little effect on RANKL mRNA expression and downregulated OPG mRNA expression in a donor-dependent manner. Regression analysis showed that RANKL mRNA expression was associated negatively with the percentage of cells expressing AP (p < 0.01) in vitD3- and dexamethasone-treated NHBCs. In contrast, RANKL mRNA expression was associated positively with the percentage of STRO-1+ cells (p < 0.01). In NHBCs sorted by FACS based on STRO-1 expression (STRO-1bright and STRO-1dim populations), it was found that vitD3 upregulated the expression of RANKL mRNA preferentially in STRO-1bright cells. The results suggest that immature osteoblasts respond to osteotropic factors in a potentially pro-osteoclastogenic manner. Additionally, the dual roles of osteoblasts, in supporting osteoclastogenesis or forming bone, may be performed by the same lineage of cells at different stages of their maturation.

Integrity signals

Registry

Crossref · 10.1359/jbmr.2003.18.6.1088

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Immature osteoblasts respond to bone regulatory factors in a pro-osteoclastogenic manner, but during maturation they lose RANKL expression and do not support osteoclastogenesis.

    “Immature osteoblasts respond to bone regulatory factors in a pro-osteoclastogenic manner, but during the maturation process, they lose RANKL expression and do not support osteoclastogenesis.272”

The citation lists haven’t been fetched yet

References 51 · Cited by 245

Authors
Atkins, G. J., Kostakis, P., Pan, B., Farrugia, A., Gronthos, S., Evdokiou, A., Harrison, K., Findlay, D. M., & Zannettino, A. C.
Affiliations
  • The University of Adelaide (AU)
  • South Australia Pathology (AU)
  • Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
Corresponding author
Atkins, Gerald J
Venue
Journal of Bone and Mineral Research
Published
2003-06-01
Volume
18
Issue
6
Pages
1088-1098
ISSN
  • 0884-0431 (ISSN-L)
  • 1523-4681
OpenAlex
W1997581290
Cited by
245
References
51
Citations by year
2026: 1 · 2025: 4 · 2024: 8 · 2023: 5 · 2022: 10 · 2021: 14 · 2020: 10 · 2019: 10 · 2018: 9 · 2017: 13 · 2016: 4 · 2015: 14 · 2014: 16 · 2013: 12 · 2012: 10
FWCI
3.80
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Bone and Mineral Research (publishedVersion)
  • PubMed (publishedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Funders
  • Eli Lilly and Company
  • National Health and Medical Research Council
  • National Medical Research Council
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Rheumatology › Bone and Dental Protein Studies
Keywords
RANKL, osteogenic differentiation, osteoclastogenesis, STRO-1, alkaline phosphatase, osteoprotegerin, 1,25-dihydroxyvitamin D3, dexamethasone, osteoblast proliferation, bone formation, osteoblast lineage
MeSH terms
Carrier Proteins, Cell Differentiation, Cell Division, Cells, Cultured, Dexamethasone, Fluoresceins, Fluorescent Dyes, Gene Expression Regulation, Glyceraldehyde-3-Phosphate Dehydrogenases, Humans, Membrane Glycoproteins, Osteoblasts, Phenotype, RNA, Messenger, Succinimides, Transcription, Genetic, Vitamin D, Reverse Transcriptase Polymerase Chain Reaction, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review